Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data
Jeffrey A. Scott(Integra (United States)), Rushir J. Choksi(UPMC Hillman Cancer Center)
Cited by 53
Related Papers
No related papers found
Powered by citation graph analysis